Literature DB >> 33240356

Medical management, orofacial findings, and dental care for the client with major depressive disorder.

Aviv Ouanounou1, Kester Ng2.   

Abstract

Depression is a common mental illness affecting millions worldwide. It is characterised by several symptoms including persistent sadness, constant irritability, and the loss of interest in pleasurable activities. The medical management of depression includes psychotherapy and pharmacotherapy. Depression is associated with numerous oral findings such as diminished salivary flow, rampant dental decay, advanced periodontal disease, and oral dysesthesias. Many of the oral findings in clients with depression can be due to the disease itself or to the treatment used for the condition; it can be difficult to determine which came first. Dental practitioners need to be aware of these orofacial findings and to treat and manage these clients appropriately. This short communication reviews the pharmacotherapy of depression and the effects of the drugs commonly used. Necessary dental treatment modifications for clients with depression are discussed.
Copyright © 2019, CDHA | ACHD.

Entities:  

Keywords:  antidepressants; depression; oral manifestations; periodontal disease; xerostomia

Mesh:

Year:  2019        PMID: 33240356      PMCID: PMC7533804     

Source DB:  PubMed          Journal:  Can J Dent Hyg        ISSN: 1712-171X


  38 in total

Review 1.  Medically unexplained chronic orofacial pain. Temporomandibular pain and dysfunction syndrome, orofacial phantom pain, burning mouth syndrome, and trigeminal neuralgia.

Authors:  J J Marbach
Journal:  Med Clin North Am       Date:  1999-05       Impact factor: 5.456

Review 2.  Depression in Parkinson's disease: impediments to recognition and treatment options.

Authors:  W Poewe; E Luginger
Journal:  Neurology       Date:  1999       Impact factor: 9.910

Review 3.  Xerostomia: etiology, recognition and treatment.

Authors:  James Guggenheimer; Paul A Moore
Journal:  J Am Dent Assoc       Date:  2003-01       Impact factor: 3.634

Review 4.  Diagnosis and treatment of depression in late life. Consensus statement update.

Authors:  B D Lebowitz; J L Pearson; L S Schneider; C F Reynolds; G S Alexopoulos; M L Bruce; Y Conwell; I R Katz; B S Meyers; M F Morrison; J Mossey; G Niederehe; P Parmelee
Journal:  JAMA       Date:  1997-10-08       Impact factor: 56.272

5.  Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication.

Authors:  J Kirchheiner; H Schmidt; M Tzvetkov; J-T H A Keulen; J Lötsch; I Roots; J Brockmöller
Journal:  Pharmacogenomics J       Date:  2006-07-04       Impact factor: 3.550

6.  A central nervous system defect in biosynthesis of corticotropin-releasing hormone is associated with susceptibility to streptococcal cell wall-induced arthritis in Lewis rats.

Authors:  E M Sternberg; W S Young; R Bernardini; A E Calogero; G P Chrousos; P W Gold; R L Wilder
Journal:  Proc Natl Acad Sci U S A       Date:  1989-06       Impact factor: 11.205

Review 7.  Anesthetic Considerations for Patients on Antidepressant Therapy-Part I.

Authors:  Mana Saraghi; Leonard R Golden; Elliot V Hersh
Journal:  Anesth Prog       Date:  2017

8.  Major depressive disorder. Psychopathology, medical management and dental implications.

Authors:  A H Friedlander; M E Mahler
Journal:  J Am Dent Assoc       Date:  2001-05       Impact factor: 3.634

9.  Long-term use of antidepressants for depressive disorders and the risk of diabetes mellitus.

Authors:  Frank Andersohn; René Schade; Samy Suissa; Edeltraut Garbe
Journal:  Am J Psychiatry       Date:  2009-04-01       Impact factor: 18.112

10.  Burden of depressive disorders by country, sex, age, and year: findings from the global burden of disease study 2010.

Authors:  Alize J Ferrari; Fiona J Charlson; Rosana E Norman; Scott B Patten; Greg Freedman; Christopher J L Murray; Theo Vos; Harvey A Whiteford
Journal:  PLoS Med       Date:  2013-11-05       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.